Clinical Trials Directory

Trials / Completed

CompletedNCT01306006

The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
3,500 (estimated)
Sponsor
Bandim Health Project · Academic / Other
Sex
All
Age
9 Months – 35 Months
Healthy volunteers
Accepted

Summary

The national Expanded Programme on Immunization (EPI) in Guinea-Bissau focuses its efforts exclusively on children below 12 months of age; children who have reached 12 months of age are no longer entitled to vaccines through the EPI program. This has affected the measles vaccination coverage, approx. 30% of the children in the rural area do not receive measles vaccine (MV). Studies from the Bandim Health Project (BHP) have shown that MV has a profound impact on survival, reducing mortality by approximately 50% - far more than can be explained by prevention of measles deaths. Hence, MV seems to have non-specific beneficial effects on survival, and the current policy may have important consequences for overall child mortality. To test the implications of the current policy of only vaccinating children below 12 months of age, the investigators will conduct a cluster randomized trial, in which children will receive their vaccines according to the current national EPI policy (National policy) or receive MV regardless of age and whether some doses of MV may be lost (MV-for-all policy). The investigators hypothesise that among children enrolled after 12 months of age, mortality is 50% lower in children randomised to receive MV compared with children randomised to follow the national policy and not receive MV.

Conditions

Interventions

TypeNameDescription
BIOLOGICALProviding measles vaccine for all children 9-35 months who have not yet received a routine measles vaccineNormal measles vaccines licensed for distribution through the national EPI program

Timeline

Start date
2011-02-01
Primary completion
2017-12-02
Completion
2017-12-02
First posted
2011-03-01
Last updated
2026-02-11

Locations

1 site across 1 country: Guinea-Bissau

Source: ClinicalTrials.gov record NCT01306006. Inclusion in this directory is not an endorsement.